Allogene Therapeutics (ALLO) EV/FCF: History & Chart

Allogene Therapeutics, Inc.(ALLO)

Biotechnology · South San Francisco, CA

$1.49-0.01 (-0.67%)

Delayed quote: Oct 6, 2026, 9:35 AM EDT

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.

South San Francisco, CA

151 employees

www.allogene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Zachary Roberts

View full financials

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Allogene Therapeutics, Inc. (ALLO)	$514.28M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$521.19M	N/A	0.12x	0.12x	0.12x
NeoGenomics, Inc. (NEO)vs ›	$502.08M	N/A	51.06x	46.23x	33.62x
Crescent Biopharma, Inc. (CBIO)vs ›	$534.87M	N/A	N/A	N/A	N/A
Bright Minds Biosciences Inc. (DRUG)vs ›	$492.29M	N/A	N/A	N/A	N/A
Evolus, Inc. (EOLS)vs ›	$487.33M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$541.30M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$548.86M	28.78x	31.80x	42.09x	42.09x
Cerus Corporation (CERS)vs ›	$479.49M	N/A	997.52x	857.93x	857.93x
Contineum Therapeutics, Inc. (CTNM)vs ›	$479.41M	N/A	36.88x	36.88x	36.88x

NAME

MARKET CAP

EV/FCF RATIO

TTM

Allogene Therapeutics, Inc. (ALLO)

$514.28M

N/A

Altimmune, Inc. (ALT)vs ›

$521.19M

N/A

0.12x

NeoGenomics, Inc. (NEO)vs ›